Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company operates within the biopharmaceutical and immunology industries, with a strategic emphasis on conditions driven by dysregulated immune responses. Its core value proposition is the development of biologic therapies designed to achieve high efficacy with differentiated dosing profiles and patient convenience.
The company’s primary business revolves around the development of sonelokimab, a next-generation IL-17A and IL-17F inhibiting nanobody. MoonLake targets large autoimmune markets with significant unmet medical need, including dermatology and rheumatology indications. The company was founded in 2020 and is headquartered in Switzerland, with additional operational presence in the United States. MoonLake became publicly traded through a merger with a special purpose acquisition company (SPAC) in 2022, which provided capital to advance its clinical pipeline.
Business Operations
MoonLake operates as a single-segment clinical-stage biotechnology company, with substantially all activities focused on research and development of immunotherapies. Its lead asset, sonelokimab, is being evaluated in multiple Phase 3 and late Phase 2 clinical programs for diseases such as hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis. The company does not generate product revenue and relies on equity financing to fund operations.
The company’s technology platform is based on Nanobody® antibody engineering, licensed from Ablynx NV, enabling smaller molecular size, high tissue penetration, and potential for less frequent dosing. MoonLake does not maintain internal manufacturing at commercial scale and instead relies on third-party contract research organizations and manufacturing partners. As of public disclosures, the company does not report revenue-generating subsidiaries or joint ventures.
Strategic Position & Investments
MoonLake’s strategy centers on positioning sonelokimab as a best-in-class IL-17 pathway inhibitor capable of competing with and differentiating from existing biologics. Key growth initiatives include advancing multiple Phase 3 trials in parallel and expanding the clinical footprint of its lead asset into additional inflammatory indications.
The company’s principal investment is in its clinical development pipeline rather than acquisitions or a diversified portfolio. MoonLake has not announced completed acquisitions of other biotechnology companies but has made significant financial commitments to late-stage clinical trials and long-term manufacturing agreements. Its strategic focus remains tightly concentrated on immunology, with no disclosed expansion into oncology or other therapeutic areas as of the latest public filings.
Geographic Footprint
MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, with significant operational and clinical development activities in the United States. The company’s clinical trials are conducted across North America, Europe, and other international regions, reflecting a global development strategy aligned with regulatory approval pathways in major pharmaceutical markets.
While MoonLake does not maintain large-scale commercial operations, its international footprint is shaped by global clinical trial sites, regulatory engagement with agencies such as the U.S. FDA and European Medicines Agency, and collaborations with multinational service providers. The company’s investor base and public listing further extend its market presence into global capital markets.
Leadership & Governance
MoonLake is led by an executive team with experience in immunology, biologics development, and global pharmaceutical commercialization. The leadership emphasizes disciplined clinical execution, focus on differentiated science, and efficient capital allocation to maximize long-term shareholder value.
Key executives include:
- Jorge Santos da Silva – Chief Executive Officer
- Yi Liu – Chief Financial Officer
- Tobias Zell – Chief Operating Officer
- Sven Schuetzle – Chief Development Officer
- Thomas Staehelin – Chairman of the Board
The board and management team include individuals with prior leadership roles at major biotechnology and pharmaceutical companies, reflecting a governance structure oriented toward advancing late-stage clinical assets toward regulatory approval and potential commercialization.